Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2020-03-30 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / ....
Regulatory Filings
2020-03-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Cipla's receipt of final approval from the US FDA for a generic version of AstraZeneca's Nexium. It is addressed to stock exchanges and includes a summary of the product and company background. The document is short (4284 characters) and does not contain any financial data, regulatory filings, or detailed reports. It is an announcement of a corporate event (product approval) rather than a financial or regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2020-03-26 English
Press Release - Cipla receives final approval for generic version of AstraZeneca Pharmaceutical's Nexium® (Esomeprazole for Oral Suspension 10mg, 20mg and 40mg)
Regulatory Filings
2020-03-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges and a Luxembourg stock exchange, notifying them about the schedule of analyst and institutional investor meetings. It references regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure obligations. The content is a notification of upcoming meetings rather than a financial report, earnings release, or any detailed financial data. The document length is short (1823 characters), and it does not contain financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2020-03-24 English
Please find enclosed letter regarding the schedule of Analyst / Institutional Investor meeting of the Company.
Regulatory Filings
2020-03-24 English
Updates
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no textual content or substantive information. The true document length is only 230 characters, which is very short and contains no report or announcement text. There is no indication of any report, announcement, or filing type. Given the lack of content, this document cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2020-03-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.